Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC

Por: Felip, E, Brunsvig, P, Helland, A, Vinolas, N, Aix, S, Carcereny, E, Gomez, MD, Perez, JMT, Arriola, E, Campelo, RG, Spicer, J, Thompson, J, Granados, ALO, Holt, R, Smethurst, D, Lorens, J, Shoaib, M, Siddiqui, A, Schoelermann, J, Lorens, K, Schmidt, E, Chisamore, MJ and Krebs, M

---

Publicada: 1 oct 2019

---

---

Filiaciones:
Felip, E:
 Vall dHebron Univ Hosp, Barcelona, Spain

Brunsvig, P:
 Oslo Univ Hosp, Oslo, Norway

Helland, A:
 Norwegian Radium Hosp, Oslo Univ Hosp, Inst Canc Res, Oslo, Norway

Vinolas, N:
 Hosp Clin Barcelona, Barcelona, Spain

Aix, S:
 Hosp 12 Octubre, Carretera Andalucia, Madrid, Spain

:
 Catalan Inst Oncol Badalona, Med Oncol, Badalona, Spain

 Hosp Badalona Germans Trias & Pujol, Badalona, Spain

 B Argo, Badalona, Spain

Gomez, MD:
 Hosp Univ Fdn Jimenez Diaz, Madrid, Spain

Perez, JMT:
 Hosp Virgen de la Victoria, Malaga, Spain

Arriola, E:
 Hosp del Mar, Oncol, Barcelona, Spain

Campelo, RG:
 Univ Hosp A Coruna Xxiac Sergas, Med Oncol Serv, La Coruna, Spain

Spicer, J:
 KingS Coll London, Guys Hosp, London, England

Thompson, J:
 Med Coll Wisconsin, Affiliated Hosp, Menomonee Falls, WI USA

Granados, ALO:
 Complejo Hosp Jaen, Med Oncol, Jaen, Spain

Holt, R:
 Bergenbio Asa, Bergen, Norway

Smethurst, D:
 Bergenbio Asa, Bergen, Norway

Lorens, J:
 Bergenbio Asa, Bergen, Norway

Shoaib, M:
 Bergenbio Asa, Bergen, Norway

Siddiqui, A:
 Bergenbio Asa, Bergen, Norway

Schoelermann, J:
 Bergenbio Asa, Bergen, Norway

Lorens, K:
 Bergenbio Asa, Bergen, Norway

Schmidt, E:
 Merck & Co Inc, Kenilworth, NJ USA

Chisamore, MJ:
 Merck & Co Inc, Rahway, NJ 07065 USA

Krebs, M:
 Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England

 Univ Manchester, Manchester, Lancs, England